BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2021;74:931-43. [PMID: 33248171 DOI: 10.1016/j.jhep.2020.11.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Sempokuya T, Forlemu A, Azawi M, Silangcruz K, Khoury N, Ma J, Wong LL. Survival characteristics of fibrolamellar hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results database study. World J Clin Oncol 2022; 13(5): 352-365 [DOI: 10.5306/wjco.v13.i5.352] [Reference Citation Analysis]
2 Cammarota A, Zanuso V, D'Alessio A, Pressiani T, Bozzarelli S, Personeni N, Rimassa L. The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35152830 DOI: 10.1080/13543784.2022.2042253] [Reference Citation Analysis]
3 Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DI, Pawlik TM. Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Rev Anticancer Ther 2022. [PMID: 35157530 DOI: 10.1080/14737140.2022.2041415] [Reference Citation Analysis]
4 Cai X, Deng J, Zhou J, Cai H, Chen Z. Cyclin-dependent kinase 19 upregulation correlates with an unfavorable prognosis in hepatocellular carcinoma. BMC Gastroenterol 2021;21:377. [PMID: 34649520 DOI: 10.1186/s12876-021-01962-8] [Reference Citation Analysis]
5 Negri F, Missale G, Antoni AD, Porta C. Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. Transl Oncol 2021;14:101153. [PMID: 34144349 DOI: 10.1016/j.tranon.2021.101153] [Reference Citation Analysis]
6 Jain A, Chitturi S, Peters G, Yip D. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World J Hepatol 2021; 13(9): 1132-1142 [PMID: 34630880 DOI: 10.4254/wjh.v13.i9.1132] [Reference Citation Analysis]
7 de Castro T, Jochheim LS, Bathon M, Welland S, Scheiner B, Shmanko K, Roessler D, Khaled NB, Jeschke M, Ludwig JM, Marquardt JU, Weinmann A, Pinter M, Lange CM, Vogel A, Saborowski A. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol 2022;14:175883592210802. [DOI: 10.1177/17588359221080298] [Reference Citation Analysis]
8 Zhang ZS, Yang RH, Yao X, Cheng YY, Shi HX, Yao CY, Gao ZX, Qi DF, Zhang WK, Dou YY, Guo J, Hu MW, Zhao H, Fang D. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma. Cell Biol Int 2021. [PMID: 34486197 DOI: 10.1002/cbin.11697] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 He J, Huo Y, Zhang Z, Luo Y, Liu X, Chen Q, Wu P, Shi W, Wu T, Tang C, Wang H, Li L, Liu X, Huang Y, Zhao Y, Gan L, Wang B, Zhong L. Generation of αGal-enhanced bifunctional tumor vaccine. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.03.002] [Reference Citation Analysis]
10 Bang YH, Lee C, Yoo C, Chon HJ, Hong M, Kang B, Kim H, Park SR, Choi W, Choi J, Lee D, Shim JH, Kim KM, Lim Y, Lee HC, Ryu M, Ryoo B. Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Ther Adv Med Oncol 2022;14:175883592210979. [DOI: 10.1177/17588359221097934] [Reference Citation Analysis]
11 Han Y, Li Z, Wu Q, Liu H, Sun Z, Wu Y, Luo J. B4GALT5 high expression associated with poor prognosis of hepatocellular carcinoma. BMC Cancer 2022;22:392. [PMID: 35410157 DOI: 10.1186/s12885-022-09442-2] [Reference Citation Analysis]
12 Wu H, Xu XF, Zhu JQ, Wang MD, Li C, Liang L, Xing H, Wu MC, Shen F, Huang DS, Yang T. Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma. Front Bioeng Biotechnol 2021;9:695635. [PMID: 34692650 DOI: 10.3389/fbioe.2021.695635] [Reference Citation Analysis]
13 D'Alessio A, Cammarota A, Prete MG, Pressiani T, Rimassa L. The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Curr Opin Oncol 2021;33:386-94. [PMID: 33867478 DOI: 10.1097/CCO.0000000000000744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Foerster F, Galle PR. The Current Landscape of Clinical Trials for Systemic Treatment of HCC. Cancers (Basel) 2021;13:1962. [PMID: 33921731 DOI: 10.3390/cancers13081962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Cammarota A, D'Alessio A, Pressiani T, Rimassa L, Personeni N. Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs Aging 2021;38:579-91. [PMID: 34152589 DOI: 10.1007/s40266-021-00871-5] [Reference Citation Analysis]
16 Malagraba G, Yarmohammadi M, Javed A, Barceló C, Rubio-tomás T. The Role of LSD1 and LSD2 in Cancers of the Gastrointestinal System: An Update. Biomolecules 2022;12:462. [DOI: 10.3390/biom12030462] [Reference Citation Analysis]
17 Cai X, Zhou J, Deng J, Chen Z. Prognostic biomarker SMARCC1 and its association with immune infiltrates in hepatocellular carcinoma. Cancer Cell Int 2021;21. [DOI: 10.1186/s12935-021-02413-w] [Reference Citation Analysis]
18 Kobayashi M, Wada H, Fukui S, Mizutani H, Ichikawa Y, Shiraki K, Moritani I, Inoue H, Shimaoka M, Shimpo H. A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms. J Clin Med 2021;10:5352. [PMID: 34830633 DOI: 10.3390/jcm10225352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd; North American AIDS Cohort Collaboration on Research, Design of IeDEA. Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. Hepatology 2021. [PMID: 33780007 DOI: 10.1002/hep.31839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Reference Citation Analysis]
21 Liu C, Li Y, Zhang L, Zhang P, Yu N, Liu X, Lu H, Du H, Hou S, Kang Z. MiRNA-196-5p Promotes Proliferation and Migration in Cholangiocarcinoma via HAND1/Wnt/β-Catenin Signaling Pathway. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/4599676] [Reference Citation Analysis]
22 Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncol 2021;17:2243-56. [PMID: 33663220 DOI: 10.2217/fon-2020-1290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]